Skip to main content

Table 7 Selected relevant pre-clinical assays based on novel drug-loaded polymeric nanoparticles for the treatment of bacterial neuroinfections

From: State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections

Bacteria Loaded molecule Polymeric matrix Surface modifications Dose Admin. route In vitro/In vivo model Results Ref
Streptococcus pneumonia Bacitracin A PLGA PEG
RGV29
P-gP inhibitor
30 mg/kg I.v Kunming mice + S. pneumonia
ATCC49619 and S. pneumonia 16,167
In vivo results further demonstrated that PNPs were able to accumulate in brain parenchyma and exhibited high therapeutic efficiencies in resistant PM mouse models with negligible systemic toxicity Hong et al. [122]
Pseudomonas aeruginosa LPS Acrylamide and N,N´-methylenebisacrylamide 5 mg/kg of NPs I.c.v Kunming mice + P. aeruginosa Selective recognition of target bacteria. Significantly strong inhibition of bacterial growth Long et al. [120]
Neisseria meningitidis CPS-A Albumin 250 µg of NPs DC2.4 cell line Surface expression of MHC I, MHC II, CD95 and co-stimulatory molecules in dendritic cells were incremented with CPS-loaded PNPs Gala et al. [119]
  1. CPS-A Meningococcal capsular polysaccharide antigen from serogroup A, LPS lipopolysaccharides from P. aeruginosa, RVG29 brain-targeted gene